families to X harbor I Good and well. for you Devin. Slide all before joining you, Slide hope Thank I aware thank your us move statement morning, make on are I on safe the and want everyone, of you of to today. you safe and X.
regimen medical with treatment see attention a to the by with We'll of providing own Finnegan him sense thousands for mission of safety in we our patients cover control. home. of discussion draw battling chronic this of system are a and conditions your when who his the freedom treat to in the left, a allowing performance In review like infusion want I who integrated comfort other our distance; strategy. open leading from chronic their few their asked to you financial are a things XX social questions. time guided COVID-XX, and like times especially just an first quality being allow first-quarter him on is topics our like can life followed Finnegan, to all products medical then conditions by by independence up to overview for people of morning, of We'll Finnegan to a that the manage and this, improve we were of
products power virus that. the and and despite our reach both our a to during safety lives, responsibility to everything say I'm the employees certainly the of a unprecedented These I'm their while manage we very protecting and proud on essential just impact daily the do serve, remarkable doing our we're And privilege has in patients and to to of challenging our KORU continue this, ensure are crisis challenging employees that their times. our proud very And takes of these through times. complete response and a It families. like health Medical team to
KORU guidelines, Medical remain York business currently state under we qualifies as New an essential and operational.
of federal, these committed safety This increased local guidelines. to and work and nonproduction to times related during safety cleaning on the suppliers demand team protocols facility. our requiring higher for we've health remotely where due distancing customers impact likely cancellation have disinfecting, restrictions, travel reactive business and products, challenging and limitations COVID-XX. to hit the with We of March, includes of uncertainty virus most frequency members following in employees, our state experiencing instituted and social practices, our been Since are to certain and events associated the purchasing the of surrounding possible, visitor access late
and products impact and schedule thus supply minimal product ship far the inventory, manufacture seen have We of production, or chain distribution to are to on currently our continuing line.
However, economic uncertainty. this situation with an is evolving
levels to in our through monitoring distributors, are to on sells which drive supply We offset keeping that KORU depend calls the from very a logistics. also sales managing potential insulates I products us slowdown effort and and inventory to in majority chain eye close revenue. also having are note medical an to the any person want of closely on in
is us these. operating an This at overlooked model, like advantages that sometimes times aspect with we provides significant but our believe one of
other is chronic Moving most item. patients point discretionary words, to conditions. infusion It's use integrated a slide. that the to important of are the freedom not the out next this In that system managing
diagnosis office. patients PIDD that into simply they may of get doctor's CIDP some delayed because their their there cannot are have who and acknowledge We
physician in mind in years place. to bear XX However, than more it can the that these secure first diagnoses take in visits multiple
supply prescriptions are issues with immunoglobulin currently So long-term respect any fulfillment as the of we minimal view to XXXX, seen not growth. disruptions. impediment with With and supply, to we a not progressing industry do this for plasma have significant and
collection effects plasma that despite continuing the is understanding COVID-XX. are efforts of Our
ramp-up Although disruption collection in it's collection and that as reasonable as state see assume soon would local to activities occur, permit. to we and a also some guidelines may federal, expect
important added situation collected drug fluid any could plasma not numbers. if industry it's plasma to The respect note, seven new today the As harvest XX does that in months. availability for the the supply landscape supply enter of context, and to is the is sufficient approximately to with change cannot
home it's our with of of although Finally, that situation, the contracting COVID-XX out fear opened I been illness too live benefits of managing to In a of some great eyes all severe afforded in glimpse that PIDD, a far look ahead have who their the sense, we into necessity has have current and healthcare. on perhaps a believe an could to health. lives patient impact tough
is CIDP. operating PIDD Our on the thesis self-administered therapy great we benefits and see based with patients with for infusion
events the of expect grow. at that we couple and will surrounding infusion continue home the the past benefits to months, the Given conversations of of subcu therapy
specialty home We shifting are subcu actively IG. to patients aware providers of IVIg infusion and pharmacies
the to Moving next slide.
infusion results first-quarter and Our and dedication were for continued our of demand of strong resilience the our employees. products, driven execution commercial by portfolio
the strong. today, here remain fundamentals business our sit of we As
markets, adjusted increases to in slight discontinuation down tick income remains benefited the due sales increased economic product penetration and $XXX,XXX EBITDA. up from into reported with related net in sales, sales. Higher We uncertainty there profit, continued gross primary was attributable noncash a net Gross to COVID-XX. our However, significant Rescue line. along clinical to trial end a margin VAC net with of gross profit charge the our
would engaged to a our its to contributions is help QX legacy can expand consulting scale this a manufacture been us significant have gross margin manufacturing-related for to XXXX. Normalizing material. more in manner. efficiencies. the of help overall explore see gross and and how margin product firm our We via This that potential were products end, a increased efficient in not XX% To results we we impact,
this adjusted the slide, is plan. of revenue rate and on designed operating goal component strategic of efficiencies strategic operated one year-end plus year. quarter and included of managing to as the gross run to $XX by our year-end goals review of our drive an each from of us to a process margin and X.X EBITDA next by million toward basis by of improved are part a toward $XXX,XXX, the financial XXXX our $XXX,XXX $XXX,XXX initiatives improving GAAP with million. our We XXXX, organic XXXX, than to XX% overall us plus income a a On we the XX% net growth business toward set generating for first goals more our advance profitably turnaround The
infusion home our key positions and on continue end We and improving customers, trial both overseas, markets, primary contractual clinical our increasing domestically our to with pharmacies revenue and specialty and solidifying focus our penetrating providers.
Super we XXXX, needle the from XXXk high the XX clearance first safety for in originally in occur was set. limited our This launch Operationally, subcutaneous quarter. scheduled FDA received to flow
was it not due However, new expect financial in product XXXX. later new We to a now launch COVID-XX. from delayed do We needle expect impact set this year. this this material to
be offering that to and helpful to product However, providers those it very our may us allowing in patients prefer expand infusions. faster
growth CSL in late focus Xembify, we that to which Grifols, support our which as products expect the for manufactures Medical. We pharmaceutical of continue on benefit launched such companies and of products, like Hizentra produce XXXX. KORU sales sales to incremental positive the to Behring, providing of makers continue product will Xembify, HIZENTRA Growing and new
Grifols modality preferred infusion. market, infusion is their and a the market formulation the versus more IVIg on subcu validates and we of subcu widely focus their in leader feel IV prescribed
with potential hematology clinical Phase IG these states. and yet be activity a COVID-XX. We of to currently as a involved some primary delays recently of although but the subcutaneous includes system trial the met freedom trial in actively continue III opportunities, drug as other is in multiple that Our of launch. for to clinical plan result associated pursue completed development expansion a area endpoint its This trials with of in efficacy there disease contemplated defined therapies may
that are are our conditions. much future energy and well made near On next the world market we positioned current of to navigate keeping eye we an to term. imperative that on the events toward the focus have we believe slide, it Regardless,
unique integrated first have that provided with mover in technology freedom a We advantages. our us infusion has mechanical system
at significant strong relationships share, pharmaceutical toward care. strong migration home at the are have industry supporting market We and
improve outcomes of quality compliance, our are confident benefits use who enhance Most products and we patients life tangible deliver to them. that the importantly,
of avenues long-term for a and to review growth. of includes space see While we of themes, leverage trials participation international these for use use therapies, will turn clinical current things drugs we new over This increasing our the beyond for our Karen? continue several first-quarter Karen expansion. I in and expanded now growing IG therapy, sustainable to existing results.
